Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

July 31, 2016

Conditions
Urothelial Carcinoma
Interventions
DRUG

Mocetinostat

Trial Locations (14)

10065

Memorial Sloan Kettering Cancer Center, New York

14627

University of Rochester, Rochester

21287

Johns Hopkins University, Baltimore

27599

University of North Carolina, Chapel Hill

33905

Florida Cancer Specialists, Fort Myers

35294

University of Alabama, Birmingham

43210

Ohio State University, Columbus

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan, Ann Arbor

60637

University of Chicago, Chicago

63110

Washington University, St Louis

84112

Huntsman Cancer Institute, Salt Lake City

91010

City of Hope National Medical Center, Duarte

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT02236195 - Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | Biotech Hunter | Biotech Hunter